Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00598988
Other study ID # 6866
Secondary ID
Status Terminated
Phase Phase 2/Phase 3
First received
Last updated
Start date January 2008
Est. completion date December 2008

Study information

Verified date May 2017
Source University of Alberta
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to investigate feasibility issues related to conducting an acupuncture study in a population of adolescents and young adults with infectious mononucleosis. Additionally, this study will provide preliminary data regarding treatment parameters (acupuncture and standard care) and outcomes (i.e. fatigue).


Description:

This study examines the feasibility of treating adolescents and young adults diagnosed with infectious mononucleosis with acupuncture. Additionally, this study will provide preliminary data regarding treatment parameters (acupuncture and standard care) and outcomes (i.e. fatigue).


Recruitment information / eligibility

Status Terminated
Enrollment 3
Est. completion date December 2008
Est. primary completion date December 2008
Accepts healthy volunteers No
Gender All
Age group 15 Years to 25 Years
Eligibility Inclusion Criteria: - mono diagnosis confirmed by lab test - 21 days or less between start of symptoms and diagnostic test - presence of fatigue of at least 4/11 (by Chalder Fatigue Questionnaire) - no other illnesses present - meets residency requirement Exclusion Criteria: - insufficient communication in English - unable to begin acupuncture within 21 days of diagnostic test - acupuncture use currently or in the preceding 3 months - currently under the care of a TCM practitioner - unwilling to be randomized

Study Design


Intervention

Procedure:
traditional Chinese acupuncture
10 treatments over 6 weeks
Other:
standard medical care
standard care as provided by primary physician

Locations

Country Name City State
Canada University of Alberta Edmonton Alberta

Sponsors (1)

Lead Sponsor Collaborator
University of Alberta

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Chalder Fatigue Questionnaire 12 weeks
Secondary MOS SF-36 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05683834 - Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons Phase 1/Phase 2
Completed NCT00575185 - Activity of Valomaciclovir in Infectious Mononucleosis Due to Primary Epstein-Barr Virus Infection Phase 1/Phase 2
Active, not recruiting NCT04645147 - Safety and Immunogenicity of an Epstein-Barr Virus (EBV) gp350-Ferritin Nanoparticle Vaccine in Healthy Adults With or Without EBV Infection Phase 1
Completed NCT06002802 - Study on Infectious Mononucleosis in Munich
Not yet recruiting NCT02715037 - Microbiology of Severe Acute Tonsillitis, Peritonsillar Cellulitis, and Infectious Mononucleosis N/A
Withdrawn NCT04138875 - A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB) Phase 2
Recruiting NCT05225493 - HIV Indicator Diseases in Hospital and Primary Care
Completed NCT00274404 - Controlled Trial of Valacyclovir in Infectious Mononucleosis Phase 1/Phase 2
Terminated NCT02463669 - The Use of Point-of-Care Ultrasound in the Diagnosis of Acute Infectious Mononucleosis in the Emergency Department